CN115667278A - 乏氧活化的dna烷化剂及其医药用途 - Google Patents

乏氧活化的dna烷化剂及其医药用途 Download PDF

Info

Publication number
CN115667278A
CN115667278A CN202180036541.8A CN202180036541A CN115667278A CN 115667278 A CN115667278 A CN 115667278A CN 202180036541 A CN202180036541 A CN 202180036541A CN 115667278 A CN115667278 A CN 115667278A
Authority
CN
China
Prior art keywords
compound
cancer
tumor
group
impaired
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180036541.8A
Other languages
English (en)
Inventor
李安蓉
段建新
孟繁英
蔡晓宏
齐天阳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Ascentawits Pharmaceutical Technology Co ltd
Original Assignee
Shenzhen Ascentawits Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Ascentawits Pharmaceutical Technology Co ltd filed Critical Shenzhen Ascentawits Pharmaceutical Technology Co ltd
Publication of CN115667278A publication Critical patent/CN115667278A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/564—Three-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/60—Quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C07F9/650994—Six-membered rings having the nitrogen atoms in the positions 1 and 4 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

本发明涉及具有以下任一结构式的乏氧活化的DNA烷化剂，或其药学上可接受的盐或前药或溶剂合物或同位素变体，及其抗癌医药用途：
Figure DDA0003952130640000011

Description

PCT国内申请，说明书已公开。

Claims (33)

  1. PCT国内申请，权利要求书已公开。
CN202180036541.8A 2019-12-20 2021-06-23 乏氧活化的dna烷化剂及其医药用途 Pending CN115667278A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201911324466 2019-12-20
CNPCT/CN2020/114519 2020-09-10
PCT/CN2020/114519 WO2021120717A1 (zh) 2019-12-20 2020-09-10 抗癌化合物及其医药用途
PCT/CN2021/101870 WO2022052564A1 (zh) 2019-12-20 2021-06-23 乏氧活化的dna烷化剂及其医药用途

Publications (1)

Publication Number Publication Date
CN115667278A true CN115667278A (zh) 2023-01-31

Family

ID=76477075

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080067311.3A Pending CN114466853A (zh) 2019-12-20 2020-09-10 抗癌化合物及其医药用途
CN202180036541.8A Pending CN115667278A (zh) 2019-12-20 2021-06-23 乏氧活化的dna烷化剂及其医药用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202080067311.3A Pending CN114466853A (zh) 2019-12-20 2020-09-10 抗癌化合物及其医药用途

Country Status (7)

Country Link
US (2) US20230026163A1 (zh)
EP (2) EP4079738A4 (zh)
JP (1) JP2023542286A (zh)
KR (1) KR20230065309A (zh)
CN (2) CN114466853A (zh)
TW (2) TWI833055B (zh)
WO (2) WO2021120717A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118201940A (zh) * 2021-11-05 2024-06-14 深圳艾欣达伟医药科技有限公司 Akr1c3活化的dna烷化剂及其医药用途
CN114106042B (zh) * 2021-11-12 2022-09-16 深圳艾欣达伟医药科技有限公司 一种氘代化合物及其制备方法和应用
WO2023174319A1 (zh) * 2022-03-15 2023-09-21 深圳艾欣达伟医药科技有限公司 治疗brca突变癌症患者的方法
WO2024061346A1 (zh) * 2022-09-22 2024-03-28 深圳艾欣达伟医药科技有限公司 乏氧激活的化合物在制备治疗癌症患者的药物中的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617398A (en) * 1982-04-12 1986-10-14 The Research Foundation Of State University Of New York Phosphoaziridine compounds useful for treatment of tumors
WO2001004130A1 (en) * 1999-07-14 2001-01-18 Purdue Research Foundation Phosphoramide compounds
WO2004062596A2 (en) * 2003-01-09 2004-07-29 Zeneus Pharma Limited Antineoplastic ether lipid compounds having a four carbon backbone
US9278904B2 (en) * 2013-12-31 2016-03-08 Chemapotheca, Llc Synthesis of chiral amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds
ES2828026T3 (es) * 2015-03-10 2021-05-25 Obi Pharma Inc Agentes alquilantes del ADN
WO2016210175A1 (en) 2015-06-24 2016-12-29 Threshold Pharmaceuticals, Inc. Aziridine containing dna alkylating agents
KR101985778B1 (ko) * 2015-11-16 2019-06-04 아센타위츠 파마슈티컬즈 리미티드 (r)- 및 (s)-1-(3-(3-n,n-다이메틸아미노카보닐)페녹시-4-나이트로페닐)-1-에틸-n,n'-비스(에틸렌)포스포르아미데이트, 조성물 및 이의 사용 방법 및 제조
CN106279321A (zh) 2016-08-09 2017-01-04 南京医科大学 吉西他滨ProTide乏氧活化前药及其应用
CN107118231B (zh) * 2017-03-17 2019-06-07 北京大学 萘醌磷酰胺类化合物及其在作为细胞铁死亡诱导剂中的用途
CN107513057A (zh) 2017-09-06 2017-12-26 南京医科大学 一类乐伐替尼的乏氧活化前药及其应用
TW201919644A (zh) * 2017-09-29 2019-06-01 台灣浩鼎生技股份有限公司 治療血癌的方法

Also Published As

Publication number Publication date
KR20230065309A (ko) 2023-05-11
EP4079738A1 (en) 2022-10-26
TW202128188A (zh) 2021-08-01
JP2023542286A (ja) 2023-10-06
EP4079738A4 (en) 2024-04-24
WO2021120717A1 (zh) 2021-06-24
EP4212538A1 (en) 2023-07-19
WO2022052564A1 (zh) 2022-03-17
TWI833055B (zh) 2024-02-21
US20230026163A1 (en) 2023-01-26
CN114466853A (zh) 2022-05-10
TW202210083A (zh) 2022-03-16
US20230339991A1 (en) 2023-10-26
TW202135831A (zh) 2021-10-01

Similar Documents

Publication Publication Date Title
WO2022052564A1 (zh) 乏氧活化的dna烷化剂及其医药用途
US20230346786A1 (en) Chiral diaryl macrocycles and uses thereof
US11291667B2 (en) Combination therapy involving diaryl macrocyclic compounds
Cazares-Körner et al. CH-01 is a hypoxia-activated prodrug that sensitizes cells to hypoxia/reoxygenation through inhibition of Chk1 and Aurora A
TW200811185A (en) Fused pyrimidones and thiopyrimidones, and uses thereof
EP3672595A1 (en) Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
US20210000966A1 (en) Hsp90-targeting conjugates and formulations thereof
Cruz-Collazo et al. Efficacy of Rac and Cdc42 inhibitor MBQ-167 in triple-negative breast cancer
CN109553608A (zh) 一类五元六元杂环化合物及其制备方法和治疗肿瘤的用途
US10710993B2 (en) Benzofuran pyrazole amine kinase inhibitor
TW201711679A (zh) 脲基氮芥於癌症治療上之用途
CN107184572B (zh) 一种ape1抑制剂及其在制备用于治疗肿瘤和血管异常增生性疾病药物中的应用
WO2023174319A1 (zh) 治疗brca突变癌症患者的方法
KR102055176B1 (ko) 암 치료용 키나제 저해제
Yin et al. Novel mitochondria-based targeting restores responsiveness in therapeutically resistant human lung cancer cells
US11325905B2 (en) Imidopiperidine compounds as inhibitors of human polynucleotide kinase phosphatase
US20220106325A1 (en) Cdk inhibitors and uses thereof
WO2023077452A1 (zh) Akr1c3活化的dna烷化剂及其医药用途
TW202421161A (zh) 抗癌化合物及其醫藥用途
TWI769470B (zh) 用於治療疾病的fak抑制劑和btk抑制劑的組合
Yuan et al. Pioneering 4, 11-Dioxo-4, 11-dihydro-1 H-anthra [2, 3-d] imidazol-3-ium Compounds as Promising Survivin Inhibitors by Targeting ILF3/NF110 for Cancer Therapy
WO2024054898A1 (en) Onvansertib and parp inhibitor combination
CN115040519A (zh) Egfr抑制剂用于治疗非常见或非经典突变的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination